As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
AAPL
TSLA
AMZN
META
AMD
NVDA
PEP
COST
ADBE
GOOG
AMGN
HON
INTC
INTU
NFLX
ADP
SBUX
MRNA
AAPL
TSLA
AMZN
META
AMD
NVDA
PEP
COST
ADBE
GOOG
AMGN
HON
INTC
INTU
NFLX
ADP
SBUX
MRNA
AAPL
TSLA
AMZN
META
AMD
NVDA
PEP
COST
ADBE
GOOG
AMGN
HON
INTC
INTU
NFLX
ADP
SBUX
MRNA
Markets
TERN
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
March 23, 2026 — 12:07 pm EDT
Written by
Jonathan Ponciano for
The Motley Fool->
-
-
-
-
-
Key Points
- Acorn Capital sold 225,000 shares of Terns Pharmaceuticals in the fourth quarter for an estimated $5.20 million.
- Meanwhile, the quarter-end value of the stake increased by $55.74 million, reflecting valuation changes including price movement.
- The post-transaction holding stood at 1,746,264 shares valued at $70.55 million.
- Terns Pharmaceuticals now accounts for 23.9% of the fund’s AUM, making it the largest single position in the portfolio.
- 10 stocks we like better than Terns Pharmaceuticals ›
On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals (NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing.
What happened
According to a filing with the Securities and Exchange Commission dated February 17, 2026, Acorn Capital Advisors reduced its position in Terns Pharmaceuticals (NASDAQ:TERN) by 225,000 shares during the fourth quarter of 2025. The estimated value of the trade was approximately $5.20 million, calculated using the average closing price for the quarter. The quarter-end value of the remaining stake reflected market valuation changes.
What else to know
- Acorn Capital Advisors’ Terns Pharmaceuticals holding now represents roughly 24% of its 13F AUM after the recent sale.
- Top holdings after the filing:- NASDAQ:TERM: $70.55 million (23.9% of AUM)
- NASDAQ:CGON: $46.98 million (15.9% of AUM)
- NASDAQ:URGN: $33.92 million (11.5% of AUM)
- NASDAQ:TRVI: $26.85 million (9.1% of AUM)
- NASDAQ:PBYI: $24.58 million (8.3% of AUM)
- As of Monday, shares of Terns Pharmaceuticals were priced at $50.08, up a staggering 1,400% over the past year and significantly outperforming the S&P 500’s roughly 15% gain in the same period.
Company overview
MetricValuePrice (as of Monday)$50.08Market Capitalization$5.5 billionNet Income (TTM)($94.44 million)Company snapshot
- Terns Pharmaceuticals develops clinical-stage small-molecule therapies targeting non-alcoholic steatohepatitis (NASH) and obesity, with lead candidates including TERN-101, TERN-201, TERN-501, and TERN-601.
- The firm operates a research-driven business model focused on advancing proprietary drug candidates through clinical trials, with future revenue anticipated from successful commercialization and potential partnerships.
- It targets healthcare providers, biopharmaceutical partners, and patients affected by NASH and metabolic diseases, primarily within the United States and global markets.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for NASH and metabolic disorders. With a focused pipeline of differentiated small-molecule drug candidates, the company leverages advanced research and clinical development capabilities to address significant unmet medical needs. Its strategy centers on advancing proprietary compounds through clinical milestones to establish a competitive position in the biotechnology sector.
What this transaction means for investors
Terns has been a standout in biotech, with shares skyrocketing about 1,400% in just a year. That’s the type of dramatic gain that can usually trigger some repositioning among investors, even those who still believe in the company’s future. And in this case, even after scaling back, Terns is still the fund’s largest holding, making up nearly a quarter of its assets, which is certainly an indication of strong conviction rather than a retreat.
Operationally, Terns has pivoted to focus on oncology, with promising early efficacy and safety results in treating chronic myeloid leukemia. Plus, the company wrapped up the year with around $1 billion in cash, providing a runway that extends to 2031 and the flexibility to advance toward pivotal trials. That setup has helped shares continue their ascent since the end of last quarter, climbing some 25%.
Ultimately, in this portfolio, Terns stands tall among other high-conviction biotech investments and reinforces a strategy that favors asymmetric outcomes over mere diversification.
Should you buy stock in Terns Pharmaceuticals right now?
Before you buy stock in Terns Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Terns Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netfli